caa a22 4500 46907440X CHVBK 20180323132931.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741554 doi (NATIONALLICENCE)springer-10.1007/BF01741554 Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck [Elektronische Daten] [Daniel Vlock, Beth Arnold, Jeannette Humpierres, Donald Schwartz, Shan Baker, Charles Krause, Neil Swanson, Thomas Carey] Summary: In previous studies we evaluated the incidence and specificity of autologous antibody reactivity against squamous cell carcinoma of the head and neck (SCCHN). We were able to demonstrate that autologous antibody reactivity is present in native sera but was usually of too low a titer to allow further analysis. Dissociation of immune complexes by acidification and ultrafiltration of serum augmented autologous antibody reactivity in nine out of nine autologous systems tested. Native antibody and antibody derived from immune complexes produced by the host and reactive with autologous tumor cells may be directed against physiologically relevant antigens. Therefore, correlations of antibody titers with clinical course may provide insight into the nature of the host response to cancer. In the present analysis, serological studies of six patients with SCCHN were performed with serum samples obtained over many months. Results of serial serological assays were correlated to tumor progression and clinical course. Fluctuations in autologous antibody reactivity were noted over time. In four cases, rises in autologous antibody titers preceded the clinical diagnosis of recurrence by several months. Drops in autologous antibody reactivity were noted in two cases following surgery or radiation therapy. In two cases of long-term survivors, no correlation between antibody reactivity and clinical course was noted. Specificity analysis of the six autologous systems demonstrated reactivity against autologous and allogeneic SCCHN as well as melanoma cell lines. These sera did not react with glioma, neuroblastoma, renal cell, breast, bladder and colon carcinoma cell lines nor with fetal calf serum, pooled lymphocytes, red blood cells and platelets. Autologous serial serological studies may provide a means by which to evaluate the host/tumor relationship in patients with SCCHN. Springer-Verlag, 1992 Autologous antibodies nationallicence Head and neck squamous cell carcinoma nationallicence Immune complexes nationallicence Host/tumor relationship nationallicence Vlock Daniel Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, 15240, Pittsburgh, PA, USA aut Arnold Beth Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, 15240, Pittsburgh, PA, USA aut Humpierres Jeannette Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, 15240, Pittsburgh, PA, USA aut Schwartz Donald Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut Baker Shan Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut Krause Charles Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut Swanson Neil Department of Dermatology, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut Carey Thomas Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 329-336 0340-7004 34:5<329 1992 34 262 https://doi.org/10.1007/BF01741554 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741554 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vlock Daniel Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, 15240, Pittsburgh, PA, USA aut NATIONALLICENCE 700 1- Arnold Beth Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, 15240, Pittsburgh, PA, USA aut NATIONALLICENCE 700 1- Humpierres Jeannette Division of Medical Oncology, Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine and the VA Medical Center, 15240, Pittsburgh, PA, USA aut NATIONALLICENCE 700 1- Schwartz Donald Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut NATIONALLICENCE 700 1- Baker Shan Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut NATIONALLICENCE 700 1- Krause Charles Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut NATIONALLICENCE 700 1- Swanson Neil Department of Dermatology, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut NATIONALLICENCE 700 1- Carey Thomas Department of Otolaryngology/Head and Neck Surgery, The University of Michigan School of Medicine, 48109, Ann Arbor, MI, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 329-336 0340-7004 34:5<329 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer